Aparito - a wholly owned subsidiary of Eli Lilly and Company

Aparito, a wholly owned subsidiary of Eli Lilly and Company, is revolutionizing the health care industry by digitizing clinical trials and capturing real-world data through its innovative use of mobile apps, video assessments, and wearable devices. Established in 2014 and headquartered in the United Kingdom, the company is driven by a mission to support patient-centric clinical trials and accelerate drug development for patients with life-limiting diseases.

Through its flagship product, the Atom5™ eCOA platform, Aparito collects continuous real-world data from video assessments, wearable devices, and ePROs to enhance the efficiency of clinical trials. This edge in technology provides substantial value to the health care sector, especially in an era where patient-centric approaches are increasingly prioritized.

The company’s last significant financial backing came in the form of a £1.00M Seed Round investment on 01 March 2019, with contributions from investors such as Bethnal Green Ventures, Bayer, and Wealth Club. This financial infusion underscores the confidence and interest from prominent investors in Aparito's innovative approach and potential for impact.